Penile & Urethral Cancers
Predicting Pelvic Lymph-Node Metastasis in Carcinoma Penis: A Meta-Analysis of Retrospective Studies.
- Details
Pelvic lymph node dissection (PLND) in penile squamous cell carcinoma (PSCC) adds to morbidity, which can be avoided if certain predictors are available for PLND. This meta-analysis was planned to determine the significant predictors for PLND in PSCC.
MicroRNAs in Penile Cancer: A Systematic Review of Diagnostic, Prognostic, and Mechanistic Evidence.
- Details
Penile squamous cell carcinoma (PSCC) is a rare malignancy associated with substantial morbidity and limited prognostic biomarkers. MicroRNAs have been reported as candidate molecular markers and putative regulators of tumor biology in individual PSCC studies, but their clinical relevance remains uncertain.
Prognostic Role of PD-L1 in Penile Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
- Details
Penile squamous cell carcinoma (PSCC) is a rare but aggressive malignancy, with up to 40% of patients presenting with nodal metastasis and poor survival in advanced stages. PD-L1 is an immune checkpoint molecule implicated in tumor immune evasion, yet its prognostic relevance in PSCC remains uncertain.
Unmet needs in penile cancer: Review and perspectives from the Global Society of Rare Genitourinary Tumors.
- Details
Penile cancer is an uncommon yet aggressive disease, especially at advanced stages. Management can be morbid, and patients often face a significant psychosocial impact alongside a lack of patient advocacy/support system in most parts of the globe.
Scrotal flap phalloplasty and perineal urethrostomy following total penectomy for stage IIIB penile cancer: a case report.
- Details
Penile squamous cell carcinoma is a rare malignancy that may require radical surgery in advanced stages. We report a 66-year-old male with a one-year history of a penile lesion diagnosed as verrucous squamous cell carcinoma, staged as T3N2M0 (clinical stage IIIB) based on magnetic resonance imaging findings.
Venous thromboembolism after penile cancer surgery: a UK PeCaN study.
- Details
To evaluate the incidence of venous thromboembolism (VTE) after penile cancer surgery using national hospital data and to assess current thromboprophylaxis practices across UK specialist centres.
A retrospective cohort study was conducted using Secondary Uses Service (SUS) data on penile cancer surgeries performed in NHS hospitals in England between 2015 and 2024.
Penile squamous cell carcinomas with the usual-type morphology can be HPV-associated - Routine p16/HPV testing should be performed in all penile squamous cell carcinomas regardless of morphology.
- Details
Usual-type penile squamous cell carcinoma (pSCC) is the most common pSCC subtype, categorized under the HPV-independent pSCC category in the WHO classification. Currently, guidelines do not explicitly recommend routine HPV testing in pSCCs, and pSCCs with the usual-type morphology are often presumed to be HPV-independent without further testing.
Front-line chemo-immunotherapy for advanced penile cancer: ready for prime time?
- Details
Immunotherapy has demonstrated activity in metastatic penile cancer. Shan and colleagues report encouraging safety, efficacy, and tolerability of perioperative chemoimmunotherapy in advanced disease.
A focused systematic review and meta-analysis of robot-assisted inguinal lymphadenectomy versus open inguinal lymph node dissection in penile cancer.
- Details
This focused systematic review and meta-analysis evaluated robot-assisted inguinal lymphadenectomy (RAIL) versus open inguinal lymph node dissection (OILND) in penile cancer, aiming to provide robot-specific comparative estimates rather than a broad minimally invasive synthesis.
Immunohistochemistry for p16 and p53 Provides Substantial Agreement With Molecular Tests in Penile Cancer.
- Details
Penile squamous cell carcinoma (pSCC) is a rare cancer associated with a relatively poor prognosis. The WHO classifies pSCC into HPV-associated and HPV-independent subtypes, with HPV-positive pSCCs showing slightly better outcomes.